{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:22:38Z","timestamp":1792232558768,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T00:00:00Z","timestamp":1346112000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1741-7015-10-96","type":"journal-article","created":{"date-parts":[[2012,10,4]],"date-time":"2012-10-04T16:22:17Z","timestamp":1349367737000},"source":"Crossref","is-referenced-by-count":30,"title":["Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review"],"prefix":"10.1186","volume":"10","author":[{"given":"Frank","family":"Kunath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Keck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Antes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Wullich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg J","family":"Meerpohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,28]]},"reference":[{"key":"579_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0022-5347(05)64820-3","volume":"168","author":"C Huggins","year":"2002","unstructured":"Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002, 168: 9-12. 10.1016\/S0022-5347(05)64820-3.","journal-title":"J Urol"},{"key":"579_CR2","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","volume":"59","author":"N Mottet","year":"2011","unstructured":"Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011, 59: 572-583. 10.1016\/j.eururo.2011.01.025.","journal-title":"Eur Urol"},{"key":"579_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1046\/j.1464-410x.2001.00988.x","volume":"87","author":"P Iversen","year":"2001","unstructured":"Iversen P, Melezinek I, Schmidt A: Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int. 2001, 87: 47-56. 10.1046\/j.1464-410x.2001.00988.x.","journal-title":"BJU Int"},{"key":"579_CR4","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.2165\/00003495-200262170-00006","volume":"62","author":"CI Carswell","year":"2002","unstructured":"Carswell CI, Figgitt DP: Bicalutamide: in early-stage prostate cancer. Drugs. 2002, 62: 2471-2479. 10.2165\/00003495-200262170-00006. discussion 2480-2471","journal-title":"Drugs"},{"key":"579_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0090-4295(00)00823-2","volume":"56","author":"DG McLeod","year":"2000","unstructured":"McLeod DG, Iversen P: Gynecomastia in patients with prostate cancer: a review of treatment options. Urology. 2000, 56: 713-720. 10.1016\/S0090-4295(00)00823-2.","journal-title":"Urology"},{"key":"579_CR6","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1097\/01.ju.0000140159.94703.80","volume":"172","author":"MP Wirth","year":"2004","unstructured":"Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K: Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol. 2004, 172: 1865-1870. 10.1097\/01.ju.0000140159.94703.80.","journal-title":"J Urol"},{"key":"579_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1464-410X.2005.06051.x","volume":"97","author":"DG McLeod","year":"2006","unstructured":"McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP: Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int. 2006, 97: 247-254. 10.1111\/j.1464-410X.2005.06051.x.","journal-title":"BJU Int"},{"key":"579_CR8","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.2005.12.013","volume":"23","author":"F Boccardo","year":"2005","unstructured":"Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F: Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol. 2005, 23: 808-815. 10.1200\/JCO.2005.12.013.","journal-title":"J Clin Oncol"},{"key":"579_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1470-2045(05)70103-0","volume":"6","author":"S Perdona","year":"2005","unstructured":"Perdona S, Autorino R, De Placido S, D'Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Bianco AR, Di Lorenzo G: Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol. 2005, 6: 295-300. 10.1016\/S1470-2045(05)70103-0.","journal-title":"Lancet Oncol"},{"key":"579_CR10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0090-4295(97)00457-3","volume":"50","author":"VR Staiman","year":"1997","unstructured":"Staiman VR, Lowe FC: Tamoxifen for flutamide\/finasteride-induced gynecomastia. Urology. 1997, 50: 929-933. 10.1016\/S0090-4295(97)00457-3.","journal-title":"Urology"},{"key":"579_CR11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/0026-0495(86)90237-4","volume":"35","author":"LN Parker","year":"1986","unstructured":"Parker LN, Gray DR, Lai MK, Levin ER: Treatment of gynecomastia with tamoxifen: A double-blind crossover study. Metabolism. 1986, 35: 705-708. 10.1016\/0026-0495(86)90237-4.","journal-title":"Metabolism"},{"key":"579_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2007.01.031","volume":"52","author":"Y Fradet","year":"2007","unstructured":"Fradet Y, Egerdie B, Andersen M, Tammela TLJ, Nachabe M, Armstrong J, Morris T, Navani S: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol. 2007, 52: 106-114. 10.1016\/j.eururo.2007.01.031.","journal-title":"Eur Urol"},{"key":"579_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/sj.pcan.4500782","volume":"8","author":"D Saltzstein","year":"2005","unstructured":"Saltzstein D, Sieber P, Morris T, Gallo J: Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis. 2005, 8: 75-83. 10.1038\/sj.pcan.4500782.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"579_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.eururo.2007.01.063","volume":"52","author":"G Di Lorenzo","year":"2007","unstructured":"Di Lorenzo G, Autorino R: Bicalutamide-induced gynaecomastia: do we have the answer?. Eur Urol. 2007, 52: 5-8. 10.1016\/j.eururo.2007.01.063.","journal-title":"Eur Urol"},{"key":"579_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S1470-2045(05)70464-2","volume":"6","author":"G Di Lorenzo","year":"2005","unstructured":"Di Lorenzo G, Autorino R, Perdona S, De Placido S: Management of gynaecomastia in patients with prostate cancer: a systematic review. Lancet Oncol. 2005, 6: 972-979. 10.1016\/S1470-2045(05)70464-2.","journal-title":"Lancet Oncol"},{"key":"579_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/sj.pcan.4500859","volume":"9","author":"R Autorino","year":"2006","unstructured":"Autorino R, Perdona S, D'Armiento M, De Sio M, Damiano R, Cosentino L, Di Lorenzo G: Gynecomastia in patients with prostate cancer: update on treatment options. Prostate Cancer Prostatic Dis. 2006, 9: 109-114. 10.1038\/sj.pcan.4500859.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"579_CR17","volume-title":"39th Annual Meeting of the American Society of Clinical Oncology, Chicago","author":"F Boccardo","year":"2003","unstructured":"Boccardo F, Rubagotti A, Garofalo L, Di Tonno P, Conti G, Bertaccini A, De Antoni P, Galassi P, Siragusa A, Durand F: Tamoxifen (T) is more effective than anastrozole (A) in preventing gynecomastia induced by bicalutamide (B) monotherapy in prostate cancer (pca) patients (pts). 39th Annual Meeting of the American Society of Clinical Oncology, Chicago. 2003, May 31-June 3, Abstract 1608"},{"key":"579_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00280-005-1016-1","volume":"56","author":"F Boccardo","year":"2005","unstructured":"Boccardo F, Rubagotti A, Conti G, Potenzoni D, Manganelli A, Del Monaco D: Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. Cancer Chemother Pharmacol. 2005, 56: 415-420. 10.1007\/s00280-005-1016-1.","journal-title":"Cancer Chemother Pharmacol"},{"key":"579_CR19","volume-title":"19th Congress of the European Association of Urology, Vienna","author":"G Conti","year":"2004","unstructured":"Conti G, Cretarola E, Boccardo F, Battaglia M, Di Tonno P, Bertaccini A, De Antoni P, Zattoni F, Galassi P, Durand F: Tamoxifen is safe and effective in preventing gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer and does not alter treatment efficacy. 19th Congress of the European Association of Urology, Vienna. 2004"},{"key":"579_CR20","volume-title":"22nd Annual Congress of the European Association of Urology, Berlin","author":"Y Fradet","year":"2007","unstructured":"Fradet Y, Egerdie B, Andersen M, Tammela T, Nachabe M, Armstrong J, Morris T, Navani S: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer. 22nd Annual Congress of the European Association of Urology, Berlin. 2007"},{"key":"579_CR21","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1097\/01.ju.0000181824.28382.5c","volume":"174","author":"G Di Lorenzo","year":"2005","unstructured":"Di Lorenzo G, Perdona S, De Placido S, D'Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Autorino R: Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. J Urol. 2005, 174: 2197-2203. 10.1097\/01.ju.0000181824.28382.5c.","journal-title":"J Urol"},{"issue":"Suppl 2","key":"579_CR22","first-page":"119","volume":"90","author":"D Saltzstein","year":"2002","unstructured":"Saltzstein D, Cantwell A, Sieber P, Ross JR, Silvay-Mandeau O, Gallo J: Prophylactic tamoxifen significantly reduces the incidence of bicalutamide-induced gynaecomastia and breast pain. BJU Int. 2002, 90 (Suppl 2): 119-122.","journal-title":"BJU Int"},{"key":"579_CR23","doi-asserted-by":"crossref","first-page":"e16080","DOI":"10.1200\/jco.2009.27.15_suppl.e16080","volume":"27","author":"D Bedognetti","year":"2009","unstructured":"Bedognetti D, Rubagotti A, Conti G, Francesca F, De Cobelli O, Canclini L, Galucci F, Aragona F, Di Tonno P, Boccardo F: An open, randomized, multicentre, phase III trial comparing the efficacy of two tamoxifen (T) schedules in preventing gynecomastia (gy) induced by bicalutamide monotherapy (BM) in prostate cancer patients (pca pts). J Clin Oncol. 2009, 27: e16080.","journal-title":"J Clin Oncol"},{"key":"579_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.eururo.2009.05.019","volume":"57","author":"D Bedognetti","year":"2010","unstructured":"Bedognetti D, Rubagotti A, Conti G, Francesca F, De Cobelli O, Canclini L, Gallucci M, Aragona F, Di Tonno P, Cortellini P, Martorana G, Lapini A, Boccardo F: An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. Eur Urol. 2010, 57: 238-245. 10.1016\/j.eururo.2009.05.019.","journal-title":"Eur Urol"},{"key":"579_CR25","first-page":"a1069","volume-title":"Congress of the American Urological Association, San Francisco","author":"AC Eaton","year":"2004","unstructured":"Eaton AC, Makris A: Once weekly tamoxifen in the prevention of gynaecomastia and breast pain secondary to bicalutamide therapy. Congress of the American Urological Association, San Francisco. 2004, a1069."},{"key":"579_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.juro.2010.03.137","volume":"184","author":"H Ozen","year":"2010","unstructured":"Ozen H, Akyol F, Toktas G, Eskicorapci S, Unluer E, Kuyumcuoglu U, Abay E, Cureklibatur I, Sengoz M, Yalcin V, Akpinar H, Zorlu F, Sengor F, Karaman I: Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and\/or breast pain?. J Urol. 2010, 184: 519-524. 10.1016\/j.juro.2010.03.137.","journal-title":"J Urol"},{"key":"579_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2007.01.032","volume":"52","author":"H Van Poppel","year":"2007","unstructured":"Van Poppel H: Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol. 2007, 52: 115-10.1016\/j.eururo.2007.01.032.","journal-title":"Eur Urol"},{"key":"579_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00120-007-1567-3","volume":"47","author":"H Ryssel","year":"2008","unstructured":"Ryssel H, Germann G, Kollensperger E, Riedel K: Plastic surgery for the treatment of gynaecomastia following hormone therapy in prostate carcinoma. Urologe A. 2008, 47: 467-471. 10.1007\/s00120-007-1567-3.","journal-title":"Urologe A"},{"key":"579_CR29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ijrobp.2004.03.022","volume":"60","author":"CJ Tyrrell","year":"2004","unstructured":"Tyrrell CJ, Payne H, Tammela TL, Bakke A, Lodding P, Goedhals L, Van Erps P, Boon T, Van De Beek C, Andersson SO, Morris T, Carroll K: Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys. 2004, 60: 476-483. 10.1016\/j.ijrobp.2004.03.022.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"579_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0090-4295(02)02107-6","volume":"61","author":"A Widmark","year":"2003","unstructured":"Widmark A, Fossa SD, Lundmo P, Damber JE, Vaage S, Damber L, Wiklund F, Klepp O: Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7\/SFUO-3. Urology. 2003, 61: 145-151. 10.1016\/S0090-4295(02)02107-6.","journal-title":"Urology"},{"key":"579_CR31","volume-title":"1st European Multidisciplinary Meeting on Urological Cancer, Barcelona","author":"W Mermershtain","year":"2007","unstructured":"Mermershtain W, Lazarev I, Regev E, Ariad S, Lavrenkov K: Prophylactic breast irradiation for prevention of gynecomastia caused by antiandrogen therapy with bicalutamide (casodex 150 mg\/d) for prostatic cancer patients. 1st European Multidisciplinary Meeting on Urological Cancer, Barcelona. 2007"},{"key":"579_CR32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0360-3016(86)90359-7","volume":"12","author":"D Fass","year":"1986","unstructured":"Fass D, Steinfeld A, Brown J, Tessler A: Radiotherapeutic prophylaxis of estrogen-induced gynecomastia: a study of late sequela. Int J Radiation Oncology Biol Phys. 1986, 12: 407-408. 10.1016\/0360-3016(86)90359-7.","journal-title":"Int J Radiation Oncology Biol Phys"},{"key":"579_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.eururo.2004.12.003","volume":"47","author":"H Van Poppel","year":"2005","unstructured":"Van Poppel H, Tyrrell CJ, Haustermans K, Cangh PV, Keuppens F, Colombeau P, Morris T, Garside L: Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer. Eur Urol. 2005, 47: 587-592. 10.1016\/j.eururo.2004.12.003.","journal-title":"Eur Urol"},{"key":"579_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S1470-2045(03)00958-6","volume":"4","author":"AP Dicker","year":"2003","unstructured":"Dicker AP: The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. Lancet Oncol. 2003, 4: 30-36. 10.1016\/S1470-2045(03)00958-6.","journal-title":"Lancet Oncol"},{"key":"579_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1748-717X-3-2","volume":"3","author":"C Nieder","year":"2008","unstructured":"Nieder C, Pawinski A, Andratschke NH, Molls M: Can prophylactic breast irradiation contribute to cardiac toxicity in patients with prostate cancer receiving androgen suppressing drugs?. Radiat Oncol. 2008, 3: 2-10.1186\/1748-717X-3-2.","journal-title":"Radiat Oncol"},{"key":"579_CR36","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/01.PRS.0000042146.40379.25","volume":"111","author":"RJ Rohrich","year":"2003","unstructured":"Rohrich RJ, Ha RY, Kenkel JM, Adams WP: Classification and management of gynecomastia: defining the role of ultrasound-assisted liposuction. Plast Reconstr Surg. 2003, 111: 909-923. 10.1097\/01.PRS.0000042146.40379.25. discussion 924-905","journal-title":"Plast Reconstr Surg"},{"key":"579_CR37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.5301\/JBM.2008.4771","volume":"21","author":"F Boccardo","year":"2006","unstructured":"Boccardo F, Rubagotti A, Battaglia M, Zattoni F, Bertaccini A, Romagnoli A, Conti G: Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. Int J Biol Markers. 2006, 21: 123-126.","journal-title":"Int J Biol Markers"},{"key":"579_CR38","volume-title":"23rd Annual Congress of the European Association of Urology, Milan","author":"V Serretta","year":"2008","unstructured":"Serretta V, Allegro R, De Grande G, Nicolosi F, Iurato C, Mazza R, Oxenius I, Cosentino V, Vaccarella G, Falsaperla M, Melloni D, Karydi M: Management of bicalutamide induced gynaecomastia. A randomised study comparing therapy versus prophylaxis with tamoxifen. 23rd Annual Congress of the European Association of Urology, Milan. 2008"},{"issue":"4 Supplement","key":"579_CR39","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0022-5347(08)60524-8","volume":"179","author":"V Serretta","year":"2008","unstructured":"Serretta V, De Grande G, Lapira G, Nicolosi F, Iurato C, De Giacomo E, Ranno S, Cosentino V, Contino G, Falsaperla M, Melloni D, Antonia R, Allegro R: A randomized trial comparing tamoxifen therapy versus tamoxifen prophylaxis in bicalutamide induced gynecomastia. J Urol. 2008, 179 (4 Supplement): 181.","journal-title":"J Urol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-10-96.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1741-7015-10-96\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-10-96.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:21:43Z","timestamp":1643502103000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-10-96"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,28]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["579"],"URL":"https:\/\/doi.org\/10.1186\/1741-7015-10-96","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,28]]},"article-number":"96"}}